Zloto Ofira, Vishnevskia-Dai Vicktoria, Moisseiev Joseph, Fabian Ido Didi
Goldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel.
Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2012, Tel Hashomer Israel.
Harefuah. 2018 Feb;157(2):95-98.
Uveal melanoma, the most common primary intraocular malignancy in adults, is potentially a lethal tumour. Since the development of local radiotherapy, tumour control is achieved in the majority of cases and most eyes are salvaged. Despite this, more than 50% of patients develop distant metastatic spread, mainly to the liver, and in the absence of efficient treatments to extend life, die soon after. A great deal of effort has been put into developing prognostic markers for metastatic spread and survival. Novel genetic prognostic tests, recently introduced, are now being clinically used in many ocular oncology centres worldwide. In addition, in most centres, patients are referred for systemic surveillance programs for early detection of liver metastasis. Novel treatment modalities to battle metastatic uveal melanoma are being developed and used in clinical trials. Their efficacy is yet to be proved. This review summarizes the recent developments and current challenges related to uveal melanoma management.
葡萄膜黑色素瘤是成人中最常见的原发性眼内恶性肿瘤,是一种潜在的致命性肿瘤。自从局部放疗技术发展以来,大多数病例都实现了肿瘤控制,并且大多数眼睛得以挽救。尽管如此,超过50%的患者会发生远处转移扩散,主要转移至肝脏,由于缺乏有效的延长生命的治疗方法,患者很快就会死亡。人们已经付出了巨大努力来开发用于预测转移扩散和生存情况的标志物。最近推出的新型基因预后检测方法目前正在全球许多眼科肿瘤中心临床应用。此外,在大多数中心,患者会被转诊至全身监测项目,以便早期发现肝转移。用于对抗转移性葡萄膜黑色素瘤的新型治疗方法正在研发中并用于临床试验。其疗效尚待证实。本综述总结了与葡萄膜黑色素瘤治疗相关的最新进展和当前挑战。